Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada

Key Inclusion Criteria: * Participated in Study NBI-98854-HD3006 and completing dosing through the Week 156 visit; or were actively participating, receiving study treatment, and completed an early termination visit Study NBI-98854-HD3006 at the time of the study closure at sites in Canada. * Participants of childbearing potential must agree to use contraception consistently while participating in the study until 30 days after last dose of the study treatment. Key Exclusion Criteria: * Have difficulty swallowing * Are currently pregnant or breastfeeding * Have a medically significant abnormality, physical examination finding, clinically significant laboratory abnormality